NCT01012817 - Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2009

Primary Completion Date

January 13, 2019

Study Completion Date

August 27, 2026

Conditions

Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUnresectable Solid Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacogenomic Study

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Topotecan Hydrochloride

Given IV

DRUG

Veliparib

Given PO

Trial Locations (15)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

40536

University of Kentucky/Markey Cancer Center, Lexington

55905

Mayo Clinic in Rochester, Rochester

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

University of Chicago Medicine-Orland Park, Orland Park

60637

University of Chicago Comprehensive Cancer Center, Chicago

66205

University of Kansas Clinical Research Center, Fairway

75235

Parkland Memorial Hospital, Dallas

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

80045

UCHealth University of Colorado Hospital, Aurora

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

95817

University of California Davis Comprehensive Cancer Center, Sacramento

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH